Mina Therapeutics

Mina Therapeutics company information, Employees & Contact Information

Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.

Company Details

Employees
31
Founded
-
Address
Translation & Innovation Hub, 80 Wood Lane,united Kingdom
Email
in****@****atx.com
Industry
Biotechnology
Website
minatx.com
HQ
London
Looking for a particular Mina Therapeutics employee's phone or email?

Mina Therapeutics Questions

News

MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress - Business Wire

MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress Business Wire

MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer - Business Wire

MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer Business Wire

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System - PR Newswire

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System PR Newswire

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration - PR Newswire

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration PR Newswire

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases - Business Wire

MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases Business Wire

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics - Business Wire

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics Business Wire

Top Mina Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant